imfinzi
astrazeneca ab - durvalumab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
linezolid mylan 2 mg/ml infuusioneste, liuos
mylan ireland limited mylan ireland limited - linezolidum - infuusioneste, liuos - 2 mg/ml - linetsolidi
dutasteride/tamsulosinhydrochloride mylan 0,5 mg / 0,4 mg kapseli, kova
mylan ab - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi
dutasteride mylan 0.5 mg kapseli, pehmeä
mylan ab - dutasteridum - kapseli, pehmeä - 0.5 mg - dutasteridi
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - eturauhasen kasvaimet, kastraatio-resistentin - terapeuttiset radiofarmaseuttiset valmisteet - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech
xbiotech germany gmbh - humaani iggl-monoklonaalinen vasta-aine, joka on spesifinen ihmisen interleukiini-1-alfalle - paksusuolen vajaatoiminta - antineoplastiset aineet - metastasoituneen paksu-ja peräsuolen syöpä.
fenoflox vet 100 mg/ml injektioneste, liuos
chanelle pharmaceuticals manufacturing limited - enrofloxacin - injektioneste, liuos - 100 mg/ml - enrofloksasiini
fenoflox vet 50 mg/ml injektioneste, liuos
chanelle pharmaceuticals manufacturing limited - enrofloxacin - injektioneste, liuos - 50 mg/ml - enrofloksasiini
propofol primex 10 mg/ml injektio/infuusioneste, emulsio
primex pharmaceuticals oy - propofol - injektio/infuusioneste, emulsio - 10 mg/ml - propofoli
solensia
zoetis belgium sa - frunevetmab - kipulääkkeet - kissat - for the alleviation of pain associated with osteoarthritis in cats.